U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070648) titled 'Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET' on June 24.
Brief Summary: This is a prospective, multicenter, multi-cohort study of ctDNA combined with PET for predicting the efficacy of standard first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Study Start Date: May 09
Study Type: OBSERVATIONAL
Condition:
Diffuse Large B-Cell Lymphoma
DLBCL
Intervention:
DRUG: POLA-R-CHP
Pola-R-CHP treatment for 6 cycles (IPI score 2-5)
Recruitment Status: RECRUITING
Sponsor: Fudan University
Informatio...